Tarsus Pharmaceuticals Inc logo

Tarsus Pharmaceuticals Inc

$ 16.74 -0.65 (-3.74%) 10:08 PM EST
P/E:
At Loss
P/B:
2.20
Market Cap:
$ 446.49M
Enterprise V:
$ 257.35M
Volume:
64.22K
Avg Vol (2M):
88.75K
Volume:
64.22K
Market Cap $:
446.49M
PE Ratio:
At Loss
Avg Vol (2-Month):
88.75K
Enterprise Value $:
257.35M
PB Ratio:
2.20
GF Score:
Year:
Not Enough Data to Display
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Not Enough Data to Display
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03, is a novel drug that targets the Demodex mite nervous system to kill the mites.
Name Current Vs Industry Vs History
Cash-To-Debt 11.27
Equity-to-Asset 0.86
Debt-to-Equity 0.1
Debt-to-EBITDA -0.34
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 7.8
Distress
Grey
Safe
Beneish M-Score 87.37
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -22.3
3-Year EPS without NRI Growth Rate -29.6

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 42.49
9-Day RSI 43.86
14-Day RSI 45.84
6-1 Month Momentum % 29.82
12-1 Month Momentum % -27.27

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 16.4
Quick Ratio 16.4
Cash Ratio 15.87
Days Sales Outstanding 0.38
Days Payable 2554.18

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -69

Profitability Rank

Name Current Vs Industry Vs History
Gross Margin % 96.71
Operating Margin % -384.42
Net Margin % -392.12
ROE % -34.46
ROA % -30.45
ROIC % -1636.96
ROC (Joel Greenblatt) % -3397.52
ROCE % -30.53

Financials (Next Earnings Date:2023-03-14 Est.)

TARS's 30-Y Financials

Guru Trades

See Details
To
Not Enough Data to Display

Insider Trades

See Details
To
Not Enough Data to Display

Gurus Latest Trades with NAS:TARS

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
Not Enough Data to Display

Performance

Dividend
Log
To
Not Enough Data to Display

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Not Enough Data to Display

Valuation Box

Year:
Not Enough Data to Display

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 16.154
EPS (TTM) ($) -2.78
Beta 0
Volatility % 39.35
14-Day RSI 45.84
14-Day ATR ($) 0.829216
20-Day SMA ($) 17.215
12-1 Month Momentum % -27.27
52-Week Range ($) 10.8001 - 26.9542
Shares Outstanding (Mil) 26.67

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Tarsus Pharmaceuticals Inc Filings

Document Form Filing Date
No Filing Data

Tarsus Pharmaceuticals Inc Analysis

Share your research

Headlines

See More
No news.